Literature DB >> 21953313

Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model.

Lily Nahidi1, Andrew S Day, Daniel A Lemberg, Steven T Leach.   

Abstract

BACKGROUND: Diminished intestinal epithelial barrier function contributes to the pathogenesis of Crohn's disease. Clinical and experimental studies propose that increased tumor necrosis factor (TNF)-α promotes barrier dysfunction. The aim of this study was to investigate the effects of nutritional and other therapies upon intestinal barrier function in the presence of TNF-α in an in vitro model.
METHODS: Caco-2 monolayers were grown to confluence on membrane supports and then exposed to TNF-α in the presence of polymeric formula, hydrocortisone or infliximab. Monolayer permeability was evaluated by measuring epithelial resistance, short-circuit current and horseradish peroxidase flux in an Ussing chamber. Tight junction and myosin II regulatory light-chain kinase gene expression was analysed by real-time PCR, with protein expression and localization analysed by Western blot and immunofluorescence.
RESULTS: TNF-α increased monolayer permeability and diminished tight junction integrity. However both polymeric formula and infliximab completely abrogated the effects of TNF-α. These monolayers displayed unchanged permeability and tight junction integrity compared to untreated cells (media-no-TNF-α controls). In contrast, hydrocortisone only partially abrogated the effects of TNF-α, with these monolayers having increased permeability and altered tight junction integrity compared to media-no-TNF-α controls.
CONCLUSIONS: Both polymeric formula and infliximab completely prevent epithelial barrier dysfunction in the presence of TNF-α, whereas hydrocortisone partially prevents barrier dysfunction. These results provide evidence that superior mucosal healing can be achieved with both polymeric formula and infliximab compared to hydrocortisone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953313     DOI: 10.1007/s00535-011-0471-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial.

Authors:  Osvaldo Borrelli; Letizia Cordischi; Manuela Cirulli; Massimiliano Paganelli; Valeria Labalestra; Stefania Uccini; Paolo M Russo; Salvatore Cucchiara
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-06       Impact factor: 11.382

2.  Disrupted barrier function through epithelial cell apoptosis.

Authors:  Joerg-Dieter Schulzke; Christian Bojarski; Sebastian Zeissig; Frank Heller; Alfred H Gitter; Michael Fromm
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

3.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

Review 4.  The tight junction in inflammatory disease: communication breakdown.

Authors:  Karen L Edelblum; Jerrold R Turner
Journal:  Curr Opin Pharmacol       Date:  2009-07-24       Impact factor: 5.547

5.  Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease.

Authors:  S Zeissig; N Bürgel; D Günzel; J Richter; J Mankertz; U Wahnschaffe; A J Kroesen; M Zeitz; M Fromm; J-D Schulzke
Journal:  Gut       Date:  2006-07-05       Impact factor: 23.059

6.  A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability.

Authors:  Daniel R Clayburgh; Shari Rosen; Edwina D Witkowski; Fengjun Wang; Stephanie Blair; Steven Dudek; Joe G N Garcia; John C Alverdy; Jerrold R Turner
Journal:  J Biol Chem       Date:  2004-10-26       Impact factor: 5.157

7.  Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

Authors:  Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; David F Hendricks; Gregory F Keenan; Harland S Winter
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

8.  Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro.

Authors:  Linda M Feighery; Sean W Cochrane; Teresa Quinn; Alan W Baird; Daniel O'Toole; Sian-Eleri Owens; Diarmuid O'Donoghue; Randall J Mrsny; David J Brayden
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

9.  Effect of cell polarization and differentiation on entry of Listeria monocytogenes into the enterocyte-like Caco-2 cell line.

Authors:  J L Gaillard; B B Finlay
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

10.  Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability.

Authors:  Rana Al-Sadi; Dongmei Ye; Karol Dokladny; Thomas Y Ma
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

View more
  21 in total

Review 1.  Exclusive enteral nutrition in children with Crohn's disease.

Authors:  Andrew S Day; Robert N Lopez
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

2.  The major pathway by which polymeric formula reduces inflammation in intestinal epithelial cells: a microarray-based analysis.

Authors:  Lily Nahidi; Susan M Corley; Marc R Wilkins; Jerry Wei; Moftah Alhagamhmad; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  Genes Nutr       Date:  2015-07-17       Impact factor: 5.523

3.  Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis.

Authors:  Rui Lin; Lu Zhou; Jie Zhang; Bangmao Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 4.  Manipulation of Gut Microbiota as a Key Target for Crohn's Disease.

Authors:  Reem Rashed; Rosica Valcheva; Levinus A Dieleman
Journal:  Front Med (Lausanne)       Date:  2022-06-16

5.  Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-κB activation.

Authors:  Lily Nahidi; Steven T Leach; Daniel A Lemberg; Andrew S Day
Journal:  Dig Dis Sci       Date:  2013-09-19       Impact factor: 3.199

6.  Inflammatory bowel disease therapies and gut function in a colitis mouse model.

Authors:  Lily Nahidi; Steven T Leach; Hazel M Mitchell; Nadeem O Kaakoush; Daniel A Lemberg; John S Munday; Karina Huinao; Andrew S Day
Journal:  Biomed Res Int       Date:  2013-08-06       Impact factor: 3.411

Review 7.  Enteral nutrition in Crohn's disease: an underused therapy.

Authors:  S Kansal; J Wagner; C D Kirkwood; A G Catto-Smith
Journal:  Gastroenterol Res Pract       Date:  2013-12-05       Impact factor: 2.260

Review 8.  Dietary Management in Pediatric Patients with Crohn's Disease.

Authors:  Luca Scarallo; Paolo Lionetti
Journal:  Nutrients       Date:  2021-05-11       Impact factor: 5.717

Review 9.  Nutritional Aspects of Pediatric Gastrointestinal Diseases.

Authors:  Teresa Di Chio; Christiane Sokollik; Diego G Peroni; Lara Hart; Giacomo Simonetti; Franziska Righini-Grunder; Osvaldo Borrelli
Journal:  Nutrients       Date:  2021-06-19       Impact factor: 5.717

Review 10.  Paediatric inflammatory bowel disease: a mechanistic approach to investigate exclusive enteral nutrition treatment.

Authors:  Lily Nahidi; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  Scientifica (Cairo)       Date:  2014-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.